GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company. Their product offering include vaccines, speciality medicines & general medicines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease and respiratory diseases....
This is a low risk high reward gem.
90,000 employees is too many, look for a lay-off announcement to drive down price allowing for an ideal entry at $30.00
GlaxoSmithKlein (GSK) just formed a Death Cross on the 1D time-frame, which is when the 1D MA50 (blue trend-line) crosses below the 1D MA200 (orange trend-line). This is technically a bearish pattern but last time it formed (March 24 2020) was exactly on the bottom of the COVID crash and the price recovered rapidly.
That was of course in the aftermath of the...
The stock has broken out and retested, therefore may undergo a reversal rally. Trade is supported by brokerage calls and Supports Nearby.
Risk Reward Ratio - 2.5:1
SL is placed below support zone & the lower trendline. The target is placed near resistance.
Based on historical movement, the trough could occur anywhere in the larger red box. The final targets are in the green boxes. The pending top should occur within the larger green box as has been the historical case. Half of all movement has ended in the smaller green box. In this instance, the signal indicated BUY on September 17, 2021 with a closing price of...
33 minutes ago
Hello
Welcome to this analysis about GLAXO SMITHKLINE, we are looking at daily timeframe perspectives. GLAXO SMITHKLINE in recent times heavily decreased with bearishness however it now moved into an oversold condition. GLAXO SMITHKLINE is developing here that will be a decisive factor in the upcoming times. I discovered the main formation GLAXO...
I would have expected a bull run immediately but because of the flat formation now, there might be a one wave drop before the bull run. thanks for the support. This market to me is bullish.
Moderna is the first company to start the phase 3 trial in July and could have the supply ready earliest by Oct and accelerated approval earliest by December, according to Nami Sumida/BioPharma Dive and morningstar.
Other competitors are scheduled to have accelerated approval the earliest around early 2021.
